175 related articles for article (PubMed ID: 25727651)
1. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.
Wefers C; Lambert LJ; Torensma R; Hato SV
Gynecol Oncol; 2015 May; 137(2):335-42. PubMed ID: 25727651
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.
O'Donnell T; Christie EL; Ahuja A; Buros J; Aksoy BA; Bowtell DDL; Snyder A; Hammerbacher J
BMC Cancer; 2018 Jan; 18(1):87. PubMed ID: 29357823
[TBL] [Abstract][Full Text] [Related]
3. Cellular immunotherapy for ovarian cancer.
Cannon MJ; O'Brien TJ
Expert Opin Biol Ther; 2009 Jun; 9(6):677-88. PubMed ID: 19456205
[TBL] [Abstract][Full Text] [Related]
4. Targeted immune therapy of ovarian cancer.
Knutson KL; Karyampudi L; Lamichhane P; Preston C
Cancer Metastasis Rev; 2015 Mar; 34(1):53-74. PubMed ID: 25544369
[TBL] [Abstract][Full Text] [Related]
5. The Cancer Stem Cell Niche in Ovarian Cancer and Its Impact on Immune Surveillance.
Jain S; Annett SL; Morgan MP; Robson T
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920983
[TBL] [Abstract][Full Text] [Related]
6. Targeted immunotherapy to cancer stem cells: A novel strategy of anticancer immunotherapy.
Yi SY; Wei MZ; Zhao L
Crit Rev Oncol Hematol; 2024 Apr; 196():104313. PubMed ID: 38428702
[TBL] [Abstract][Full Text] [Related]
7. The potential value of cancer-testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy.
Lin L; Zou X; Nong W; Ge Y; Li F; Luo B; Zhang Q; Xie X
Immun Inflamm Dis; 2024 Jun; 12(6):e1284. PubMed ID: 38896069
[TBL] [Abstract][Full Text] [Related]
8. Editorial: Community series in novel insights into immunotherapy targeting tumor microenvironment in ovarian cancer: volume II.
Tong A; Wang HT; Wei XW; Liang X
Front Immunol; 2023; 14():1338119. PubMed ID: 38094303
[No Abstract] [Full Text] [Related]
9. Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment.
Haines NA; Fowler MG; Zeh BG; Kriete CB; Bai Q; Wakefield MR; Fang Y
Med Oncol; 2024 Jan; 41(3):67. PubMed ID: 38286890
[TBL] [Abstract][Full Text] [Related]
10. Judith Agudo: Beware of your inner self-immune attack.
Morgado-Palacin L
J Cell Biol; 2023 Mar; 222(3):. PubMed ID: 36809460
[TBL] [Abstract][Full Text] [Related]
11. Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances.
Deng Y; Reyes RM; Zhang C; Conejo-Garcia J; Curiel TJ
J Cell Immunol; 2021; 3(6):387-396. PubMed ID: 36968176
[No Abstract] [Full Text] [Related]
12. Immunotherapeutic approaches to ovarian cancer treatment.
Chester C; Dorigo O; Berek JS; Kohrt H
J Immunother Cancer; 2015; 3():7. PubMed ID: 25806106
[TBL] [Abstract][Full Text] [Related]
13. In vitro enrichment of ovarian cancer tumor-initiating cells.
House CD; Hernandez L; Annunziata CM
J Vis Exp; 2015 Feb; (96):. PubMed ID: 25742116
[TBL] [Abstract][Full Text] [Related]
14. Stem cells, colorectal cancer and cancer stem cell markers correlations.
Cherciu I; Bărbălan A; Pirici D; Mărgăritescu C; Săftoiu A
Curr Health Sci J; 2014; 40(3):153-61. PubMed ID: 25729599
[TBL] [Abstract][Full Text] [Related]
15. New Approaches for Immune Directed Treatment for Ovarian Cancer.
Hardwick N; Frankel PH; Cristea M
Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
[TBL] [Abstract][Full Text] [Related]
16. Tumor infiltrating lymphocytes in ovarian cancer.
Santoiemma PP; Powell DJ
Cancer Biol Ther; 2015; 16(6):807-20. PubMed ID: 25894333
[TBL] [Abstract][Full Text] [Related]
17. Immune evasion in cancer: Mechanistic basis and therapeutic strategies.
Vinay DS; Ryan EP; Pawelec G; Talib WH; Stagg J; Elkord E; Lichtor T; Decker WK; Whelan RL; Kumara HMCS; Signori E; Honoki K; Georgakilas AG; Amin A; Helferich WG; Boosani CS; Guha G; Ciriolo MR; Chen S; Mohammed SI; Azmi AS; Keith WN; Bilsland A; Bhakta D; Halicka D; Fujii H; Aquilano K; Ashraf SS; Nowsheen S; Yang X; Choi BK; Kwon BS
Semin Cancer Biol; 2015 Dec; 35 Suppl():S185-S198. PubMed ID: 25818339
[TBL] [Abstract][Full Text] [Related]
18. T cell metabolic fitness in antitumor immunity.
Siska PJ; Rathmell JC
Trends Immunol; 2015 Apr; 36(4):257-64. PubMed ID: 25773310
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
Anagnostou VK; Brahmer JR
Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer.
Longoria TC; Eskander RN
Recent Pat Anticancer Drug Discov; 2015; 10(2):133-44. PubMed ID: 25938471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
